Blood gas testing is an effective tool for analysis and diagnosis of many human physiological parameters. Blood chemistry can be an effective indicator of many bodily functions and conditions. Among the vital signs of human body, respiration is a key component of a person's health. Respiratory health can be quantified by rate, volume, and blood-gas content. Traditional respiration monitoring methods such as arterial blood gas monitoring and pulse oximetry have certain advantages and disadvantages.
A transdermal patch measures a gaseous concentration based on transcutaneous diffusion through an epidermal surface of a patient. Transcutaneous oxygen and carbon dioxide differ from a measurement of saturated gases often measured in a patient blood flow or tissue. The patch employs an indicator responsive to an oxygen presence for emitting light having an intensity and lifetime based on the gaseous presence. An optical receptor is in communication with logic for receiving the intensity and lifetime (i.e. duration) of emitted light and computing the oxygen saturation or pressure level in a bimodal manner for SpO2 and PtcO2. Low power demands and circuit footprint are amenable to a wearable device such as a patch for continuous use.
The device may take the form of a bimodal oxygenation status monitoring wearable device that will continuously monitor both the transcutaneous oxygen and peripheral blood oxygen saturation and will overcome the limitations of the traditional transcutaneous oxygen monitors such as requiring a heating element and a large, expensive bedside monitor that prevents continuous monitoring outside a clinical setting.
Configurations herein are based, in part, on the observation that oxygen sensing is frequently employed in many physiologic contexts due to its prevalent nature in essential human respiration. Oxygen in various forms and concentrations is found abundantly throughout living tissue, and therefore is often a reliable indicator of proper and healthy physiology. Unfortunately, conventional approaches to oxygen monitoring rely on oxygen saturation in blood, relating to hemoglobin-bound oxygen (oxyhemoglobin) in oxygenated blood. Measurement of oxygen concentration in tissue conventionally requires a robust apparatus with heating and power requirements inconsistent with a wearable device. Oxygen concentration measures the oxygen concentration based on partial pressure of oxygen dissolved in the arterial bloodstream, and is often preferred to a measurement of oxygen saturation, or may be taken in conjunction with saturated O2.
Accordingly, configurations herein substantially overcome the shortcomings of conventional, bulky oxygen detection by providing a wearable oxygen sensor in the form of a patch or epidermal appliance for measuring transcutaneous oxygen upon diffusion through the epidermal surface. A photoluminescent indicator emits light responsive to an illuminating stimuli in a manner that varies with the presence of the diffused oxygen. An electronic circuit performs computations and implements logic for determining the oxygen concentration of the underlying tissue based on the partial pressure of the oxygen computed by the system.
In further detail, configurations below disclose an epidermal, portable, wireless transcutaneous sensing device for bimodal sensing of SpO2 and PtcO2, including a saturation sensor configured to detect a peripheral blood oxygen saturation (SpO2) based on an optical response from the skin surface, and a transcutaneous sensor configured to detect a partial pressure of transcutaneous oxygen (PtcO2) based on an optical response from a skin surface. Portability is provided by a wireless transmitter for communication with a remote server configured for rendering values corresponding to the transcutaneous oxygen and peripheral blood oxygen saturation, without a need for a heating element or large bedside monitor.
In a particular configuration directed to oxygen on the epidermal surface, the optical source emits light in a blue spectrum, and the photodetector is sensitive to light in a red spectrum. The sensing film may be a luminescent sensing film adapted for adherence to an epidermal surface. In one configuration, the luminescence of the luminophore functional groups is quenched in the presence of oxygen, reducing the intensity and lifetime of the re-emitted red light. Change in the intensity and lifetime of the re-emitted red light received by the photodetector is inversely proportional to the change in the concentration of oxygen based on the partial pressure of transcutaneous oxygen (PtcO2) diffusing from the epidermal surface. The wavelength sensitivity is specific to particular luminophores in the luminescent sensing film, as is the remitted light. Alternative sensing films may involve different wavelengths.
In contrast to conventional approaches, the PtcO2 sensor and associated logic is encapsulated in a wearable patch or low-profile, adhesive arrangement and includes a wireless transmitter for offloading storage and analytics capability. While conventional SpO2 measurement has been achieved in finger-attached wired sensors, compact sensing of PtcO2 levels has typically required a larger footprint device including a heating element for electrochemical sensing of perfusion. Therefore, conventional approaches employ an electrochemical, rather than optical measurement medium and are not feasible for miniaturization due to the power demands of the heating element, calibration and computation units.
Those skilled in the art should readily appreciate that the programs and methods defined herein are deliverable to a user processing and rendering device in many forms, including but not limited to a) information permanently stored on non-writeable storage media such as ROM devices, b) information alterably stored on writeable non-transitory storage media such as solid state drives (SSDs) and media, flash drives, floppy disks, magnetic tapes, CDs, RAM devices, and other magnetic and optical media, or c) information conveyed to a computer through communication media, as in an electronic network such as the Internet or telephone modem lines. The operations and methods may be implemented in a software executable object or as a set of encoded instructions for execution by a processor responsive to the instructions, including virtual machines and hypervisor controlled execution environments. Alternatively, the operations and methods disclosed herein may be embodied in whole or in part using hardware components, such as Application Specific Integrated Circuits (ASICs), Field Programmable Gate Arrays (FPGAs), state machines, controllers or other hardware components or devices, or a combination of hardware, software, and firmware components.
The foregoing and other objects, features and advantages of the invention will be apparent from the following description of particular embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention.
The description below presents an example of a wearable device for measurement of oxygen (O2) by transcutaneous partial pressure (PtcO2) and saturated oxygen (SpO2), which differs from conventional wearable measurement because conventional approaches solely measure saturated oxygen (SpO2). Saturated oxygen is bound to hemoglobin, while PtcO2 measurement refers to a concentration of total oxygen. Depending on the medical context, PtcO2 based readings have an advantage over conventional SpO2, either alone or in conjunction with SpO2 readings.
A blood gas measurement device includes an optical source and a sensing film adapted for adherence to an epidermal surface and responsive to gaseous diffusion from the epidermal surface. The sensing film is sensitive to the gas or gases targeted for sensing based on re-emittance properties that are affected by transdermal gaseous diffusion. An optical source, typically an LED for low power and heat properties, emits a light directed to the sensing film. A photodetector is sensitive to re-emitted light from the sensing film based on the optical source, and logic responsive to a signal from the photodetector computes a level of a blood gas based on the re-emitted light.
Photoluminescence refers to the emission of photons produced in certain molecules during de-excitation and is one of the possible physical effects resulting from the interaction between light and matter. When a luminescent molecule absorbs a photon, it is excited from a ground state to some higher energy level, and emits light upon its return to the lower state. The subsequent de-excitation processes are depicted below in
In the presence of molecular oxygen, the photoluminescence of such molecules is quenched via a radiationless deactivation process which involves molecular interaction between the quencher and the luminophore (collisional quenching) and it is therefore diffusion limited. The mechanism by which oxygen quenches luminescence is not germane to the disclosed approach, however it has been suggested that the paramagnetic oxygen causes the luminophore to undergo intersystem crossing to the triplet state while molecular oxygen goes to the excited state) and then returns to ground state.
Referring to
In the example configuration of
The skin mounted form factor of the SoC implementation 240 further includes a substrate 241 configured for epidermal mounting, a first circuit 251 including the saturation sensor 250, and a second circuit 231 including the transcutaneous sensor 230. A power supply 244 such as a Li-ion battery connects to the first and second circuits 251, 231 and the transmitter 232. In the example form factor, the system on chip (SoC) implementation 240 contains the first circuit 251, the second circuit 231 the transmitter 232, and the logic 242.
The example configuration of the saturation sensor 250 includes a red LED (light emitting diode) and an infrared (IR) LED defining the illumination sources 254, and two photodetectors 252. The photodetectors 252 are configured for measuring respective resulting photoplethysmography (PPG) signals. Photoplethysmography (PPG) refers to an optically obtained plethysmogram that can be used to detect blood volume changes in the microvascular bed of tissue, and is computed directly or indirectly from the peripheral blood oxygen saturation 255 and transcutaneous partial pressure 235 sent to the server 234. In particular, the sensing logic 242 is configured to excite the red LED and the IR LED for inducing reflections based on metabolic variations in the skin surface, where the two photodetectors 252 are responsive to the reflections.
The device 200 employs the wireless link 237 for an interface to a public access network. The remote server 234 is accessible via the public access network and is further configured for storing and coalescing a series of respective values indicative of the SpO2 and the PtcO2 for generating an indication of respiratory health.
The device of
Implementation is well suited to a wearable device in a suitable form factor where the sensor (LEDs, PDs, and sensing film) is integrated onto a substrate along with the required electrical components-a custom CMOS system-on-chip (SoC) or off-the-shelf integrated circuits (ICs)-for measurement of PtcO2 and SpO2, control, and processing. The CMOS SoC 240 integrates the readout circuitry, digital logic circuits, and wireless communications into one small, low power package that is comfortable for long-term wear. The system can do analysis of blood gas content of oxygen by measuring two vital parameters, namely PtcO2 and SpO2, giving a holistic view of the wellbeing of the patient. The system could be powered by either a wireless power link or a battery. The system would communicate using a radio with standard protocols such as Bluetooth Low Energy (BLE), Wi-Fi, ZigBee, or a customized low power protocol that could be coupled with the wireless power link. The system could also save data on the board in a non-volatile memory persistently or pending transmission via the wireless link 237.
In an example configuration, the device 100 takes the form of a wearable patch 102 adhered to or adjacent to the skin (epidermal surface) of a patient 122 for disposing a sensing circuit 150 thereon. An electronic circuit and/or processor instruction sequence implements the logic 130 which computes the oxygen concentration based on the duration and intensity of the emitted light. The photoreceptor 112 receives the light, and readout and digitizing circuits 138 transform and digitize the received light into intensity and lifetime (duration) values employed by the logic 130. A controller 132 is driven by a power supply 134 for powering the readout and digitizing electronics 138, controller 132, radio 139 and a light source driver 136 activating the LED light source 110. The controller 132 couples to the readout and digitizing circuit 138 for receiving emitted light. A radio 139 wirelessly couples to a base station 142 for gathering and transporting the computed oxygen levels, and may take the form of a personal device, hospital monitor, data logger or any suitable network device for capturing the computed oxygen levels and related data without encumbering the patient 122 with bulky devices. The patient data may then be recorded, stored and analyzed according to the patient's healthcare regimen. In contrast to conventional tethered approaches which require an electronic connection (wire), the radio 139 implements a wireless connection to a monitoring base station 142 for receiving and coalescing patient data and generating needed alerts and reports resulting from the oxygen concentration.
For example, in a particular use case, collection medium is a planar epidermal patch 102 adapted for receiving gaseous diffusion from an infant 101 patient. The ability to remotely monitor infants could improve the feasibility of early discharge and reduce the risk of undiagnosed issues becoming significant after hospital release. Continuous and accurate remote tracking of vital respiratory parameters in a fully wireless manner could provide relevant and accurate data to the caregiver to inform the course of treatment. Configurations herein address the need to monitor patience's transcutaneous oxygen level remotely and safely by a medical professional with a light and low-height profile wearable device. Conventional vital monitoring systems, especially those that monitor blood gas status are typically large, bulky bed-side machines with wired electrodes and are usually used in a hospital setting. These machines require the patient to be tethered to a hospital bed with limited mobility.
Dermal placement of the patch 102 can be made elsewhere such as the abdomen or torso where it is less susceptible to patient movement, further enhanced by the omission of wired tethers. Such a patch encloses the light sensitive medium 120 in a sealing engagement with the dermal surface 126 for quantifying the transdermal oxygen emitted or diffused through the patch.
It its most basic form, the patch 102 and sensing device 100 perform a method for sensing an oxygen concentration based on transcutaneous oxygen 124′ by receiving a diffusion of oxygen 124′ and other gases 124 through the transcutaneous surface 126. The patch 102 adheres the light sensitive medium 120 to the transcutaneous surface 126, such that the light sensitive medium 120 has a photoluminescent response to the diffused oxygen 124′. A pulsed light 111 from the light source 110 on the light sensitive medium 120 causes the photodetector 112 to receive an emitted light 121 in response to the diffused oxygen. The logic 130 computes the partial pressure of oxygen value based on an oxygen sensitive luminophore in the light sensitive medium 120 responsive to quenching of the emitted light 121 inversely with the oxygen presence. In other words, the emitted light “fades” faster with greater oxygen, now discussed in more detail below.
A low power transimpedance amplifier and low power microcontroller connect to wireless system and powered by a coin cell battery. Alternate configurations may employ any suitable power arrangement, such as a coin cell, thin film battery, wireless power link, or similar methods. The disclosed system communicates to a base station 142 using a wireless protocol, such as Bluetooth®, Bluetooth LE, ZigBee®, WiFi, NFC (Near Field Communication) or similar approach consistent with FDA (Food and Drug Administration) and other governmental recommendations or guidelines for health related devices.
In the example of
Benefits of the claimed approach will be apparent with reference to conventional approaches. Traditional devices measure PtcO2 electrochemically, using methods requiring a heating element that increases the diffusion of O2 from blood vessels, thus increasing the concentration of O2 in the gas 124 above the targeted skin area. However, a heating element negatively affects the feasibility of a miniaturized PtcO2 wearable as it substantially increases the wearable device size and the power requirement. In addition, the hotspot irritates and may even burn the skin during continuous monitoring.
To overcome such limitations, the disclosed approach employs a fluorescence-based method that allows the use of comfortable dry electrodes without the need for heating. This method uses the photoluminescent film including platinum porphyrin (Pt-porphyrin) or similar luminophore based medium. When a luminescent molecule absorbs a photon, it becomes excited from its ground state (S0) to some higher vibrational level of either the first or second electronic state (S1 or S2). When the film 120′ is exposed to blue light 411, it emits red light 421, the intensity and lifetime of which are inversely proportional to the concentration of O2 124 around the film as the energy level reaches S1 and following the excitation by the pulse of blue light, fall back to an energy level shown by S0. The fluorescence of the photoluminescent film is typically measured in terms of its lifetime (i.e. fall time) where to is the lifetime of the film fluorescence without the quencher (oxygen), and t0 is the lifetime of the fluorescence with the quencher. Conventional approaches refer to the so-called Stern-Volmer relationship in reference to the kinematics of quenching, discussed further below in
The disclosed example includes a wearable or adhesive patch having the luminescent film through which patient-diffused oxygen passes. An oxygen presence passing through or adjacent the luminescent material causes the oxygen sensitive quenching response from the optical source. Various arrangements of luminescent materials in conjunction with the patient may be employed, along with corresponding photoreceptors and optical sources with light wavelengths (colors) based on the luminescent material. Similarly, targeted gases other than oxygen may be measured based on the luminescent film and gaseous sensitivity.
The power management portion 634 may be implemented as a Power Management Integrated Circuit (PMIC) including two bandgap references (BGR) 640, two power-on-reset (POR) blocks 642, two biasing circuits, and two low-dropout (LDO) regulators 644, powered off of an external 3 V battery. The BGR 640 includes 5 V CMOS devices to withstand a wide range of battery voltages (VBATT) and generates a stable reference voltage (VREF) of 1.2 V for the LDO, which converts the battery voltage to a stable 1.8 V supply voltage (VDD). A resistive feedback network sets the relationship between VREF and VDD. When the battery voltage drops below a certain level, the POR circuit provides a power-on reset signal for the LDO. The purpose of two LDO channels is to isolate the power path between the AFE and the LED driver and to distribute the load.
For example, the LED driver 136 excites the blue LED 210 with a peak wavelength of 450 nm, which excites the Pt-porphyrin film. The film emits red light of 650 nm, the intensity and lifetime of which are inversely proportional to the concentration of O2. The current flowing through the photodetector 212 is proportional to the intensity of the red light from the film. Examples herein include Pt-porphyrin film having a sensitivity and responsiveness at the disclosed wavelengths. Alternate luminescent materials may of course be employed, such as rubidium based materials, and the wavelength values adjusted accordingly.
The LED driver 636 provides sufficient power to excite the blue LED with the proper intensity. It includes a current sensing block 650, a voltage-controlled oscillator (VCO) 652, a summer circuit, a comparator, an SR latch 654, and a driver 656, shown schematically in
The VCO generates the clock signal (CLK) and the ramp signal. VRAMP is summed with VISEN to create VSUM, which is then compared to an externally controlled reference voltage (VREFCOMP) in order to set the PWM signal. This signal resets the SR latch 654 and determines the pulse width of the DRVCTL signal. When EN is low, the driver is powered down, regardless of the DRVCTL. When enabled (EN=HIGH), VDRV controls the NMOS device based on the pulse-width modulated DRVCTL, and adjusts the current flowing through the LED. The EN signal is pulsed to reduce the power consumption of the readout. When EN is high, the LED driver pulls 16 mA current with VREFCOMP at 600 mV (increasing VREFCOMP increases IIND). When EN is low, the quiescent current of the LED driver 656, dominated by the current consumption of the VCO, is 180 mA. The externally controlled signals RAMPH, RAMPL, and VREFOSC, set the upper limit, the lower limit, and the frequency of the ramp waveform, respectively. Pulsation patterns of the blue light may vary, and are typically a series of rapid pulses interspersed between longer null intervals, as the oxygen diffusion has an inertial variance that can be effectively monitored periodically over 1-10 seconds to avoid excessive power drain.
The pulsing frequency of the system is based on the input impedance of the TIA and the capacitance of the photodetector 212. The TIA 660 may include current sensing 670-1, transimpedance 670-2, and common mode stages 670-3. The main purpose of the current-sensing stage 670-1 is to reduce the input impedance of the TIA with inner feedback loops created with amplifiers A7a and A7b and supplying a stable DC bias to the PD. The transimpedance stage 670-2 is designed to convert the current generated by the photodetector 212 to voltage with a gain of substantially around 50.1 k Ω using the feedback resistors R8 and R9 (shared with the common-mode feedback amplifier). The tunable gain is provided by the fully differential VGA 662, which follows the TIA. The variable gain is achieved by using pseudo resistors R2 and R3 controlled externally by RCTL.
The intervals of light and the wavelengths thereof are depicted above in an example arrangement. Other intensities, pulsing cycles, and wavelengths may be provided and/or varied to produce the described results, possibly with alternate granularity and precision. The logic 130 in the example circuits my be provided by any suitable logic circuit, integrated circuit and/or programmed set of instructions, executed by a processor and/or embodied in a hardware or software rendering in volatile or non-volatile memory.
An alternate configuration depicts a miniaturized wireless bimodal oxygenation status monitoring wearable device that will continuously monitor both the transcutaneous oxygen and peripheral blood oxygen saturation and also overcome the limitations of the traditional transcutaneous oxygen monitors such as requiring a heating element and a large, expensive bedside monitor. The portability and compact, nonintrusive form factor provide a viable personal device for remote monitoring of patient oxygen, which is particularly beneficial for patients with compromised respiratory systems. Healthcare providers may engage a remote network monitoring approach including a secure cloud data service that accompanies the wearable monitoring system. The patients will be provided with a monitor which will continuously record their partial pressure of oxygen (PtcO2) and peripheral blood oxygen saturation (SpO2). PtcO2 readings not only incorporate new information and additional marker to assess the respiratory efficiency and oxygenation of blood and tissues, but may also be used to correct SpO2 readings which are reported to be susceptible to skin-tone variations and motion artifacts. The PtcO2 and SpO2 readings will be sent to a server, where doctors can track the status of patients remotely.
Operationally, the overall system provides an affordable, wearable wireless sensor patch. The sensor patch can communicate via a wireless protocol to a base station which can either be medically monitored in a hospital setting or a smart device in a living environment. The data can be accessed in real-time. In addition to real time analysis, the data can also be securely stored. Post-processing of the data and customized machine learning algorithms can be applied to the stored data. This would help medical professionals conduct detailed analysis for better informed medical decisions and tailored treatment plans for the patient. This system can lead to critical observations about response to therapies and natural resolutions of different conditions. It is also an accessible solution that can help provide better care options to patients in remote locations.
The disclosed approach preferably implements a low-height profile, small form factor, low power consumption, and wireless communication capability for extended, long-term wear and comfort. The system must have comparable accuracy to contemporary “bedside” monitors. A significant feature of this sensing system is that it is a wearable wireless optical-based dual oxygenation monitoring system with no traditional heating element for transcutaneous oxygen measurement. This affords the patient improved freedom of movement, better skin compliance, and allows medical providers to receive more pertinent medical data to make better informed medical decisions and tailored treatment plans for the patients.
Following the above gas testbench experiments, configurations also demonstrate the ability of a prototype to respond to biological changes in the human body through human subject tests. For this purpose, tests were performed at the fingertips and forearms of three healthy volunteers (two males and one female). We followed two distinct methods, namely pressure-induced arterial occlusion and hypoxic gas delivery, to modulate the partial pressure of O2 diffusing through the skin to examine the prototype's response to biological changes in the body. To decrease the blood circulation through occlusion, the volunteers either clenched their index finger with the fingers of the opposite hand or a pressure cuff can be placed on their upper arm. In the latter, we inflated the cuff pressure to 180 mmHg to induce arterial occlusion, resulting in a decrease in the volunteer's PtcO2. To induce hypoxia, an altitude generator with a mask on the volunteer's face was employed. The altitude generator reduced the PO2 in the air in its reservoir and inhaled by the volunteer. The reduced O2 intake caused an overall decrease in the arterial partial pressure of oxygen (PaO2) in the body, leading to a decrease in the volunteer's PtcO2.
We conducted the first test on the first volunteer's finger by applying occlusion through clenching the index finger for three minutes. The results of this test are demonstrated in
While the system and methods defined herein have been particularly shown and described with references to embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
This patent application claims the benefit under 35 U.S.C. § 119 (e) of U.S. Provisional Patent App. No. 63/599,825, filed Nov. 16, 2023, entitled “WEARABLE OXYGEN MEASUREMENT DEVICE,” and is a Continuation-in-Part (CIP) under 35 U.S.C. § 120 of U.S. application Ser. No. 17/960,105, filed Oct. 4, 2022, entitled “TRANSCUTANEOUS GASEOUS MEASUREMENT DEVICE,” which is a Continuation-in-Part (CIP) under 35 U.S.C. § 120 of U.S. patent application Ser. No. 17/066,570, filed Oct. 9, 2020, entitled “WEARABLE BLOOD GAS MONITOR,” which claims the benefit under 35 U.S.C. § 119 (e) of U.S. Provisional Patent App. No. 62/913,299, filed Oct. 10, 2019, entitled “WEARABLE BLOOD GAS MONITOR,” and is also a Continuation-in-Part (CIP) under 35 U.S.C. § 120 of U.S. patent application Ser. No. 18/924,362 filed Oct. 23, 2024, entitled “CHARGE-TO-DIGITAL CONVERTER FOR TIME-DOMAIN DUAL LIFETIME REFERENCING,” which claims the benefit under 35 U.S.C. § 119 (e) of U.S. Provisional Patent App. No. 63/545,273, filed Oct. 23, 2023, entitled “TRANSCUTANEOUS GASEOUS MEASUREMENT DEVICE,” all incorporated herein by reference in entirety.
Number | Date | Country | |
---|---|---|---|
63545273 | Oct 2023 | US | |
63599825 | Nov 2023 | US | |
63252251 | Oct 2021 | US | |
62913299 | Oct 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17066570 | Oct 2020 | US |
Child | 17960105 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 18924362 | Oct 2024 | US |
Child | 18950028 | US | |
Parent | 17960105 | Oct 2022 | US |
Child | 18950028 | US |